SIGLEC1 — Sialic Acid-Binding Ig-Like Lectin 1
Overview
Mermaid diagram (expand to render)
SIGLEC1 (Sialic Acid-Binding Ig-Like Lectin 1), also known as CD169, Sialoadhesin, or Siglec-1, encodes a cell surface receptor belonging to the siglec family of sialic acid-binding lectins. Originally identified as a marker for activated macrophages, SIGLEC1 plays critical roles in immune recognition, cell-cell interactions, and the clearance of pathogens. More recently, SIGLEC1 has emerged as a significant factor in neurodegenerative disease pathogenesis through its involvement in neuroinflammation, amyloid-beta clearance, and immune modulation in the brain.
SIGLEC1 is expressed primarily on monocytes and macrophages throughout the body, including in the brain where it marks a specific subset of macrophages with distinct functional properties. Its ability to recognize sialylated glycans on host cells and pathogens makes it a unique interface between innate immunity and tissue homeostasis. In neurodegenerative diseases like Alzheimer's and Parkinson's, SIGLEC1-expressing macrophages may influence disease progression through their roles in clearing or potentially propagating pathological proteins.
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#c62828; color:white; text-align:center; font-size:1.1em;">SIGLEC1 Gene</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>SIGLEC1</td></tr>
<tr><td><strong>Full Name</strong></td><td>Sialic Acid-Binding Ig-Like Lectin 1</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>20p13</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[6614](https://www.ncbi.nlm.nih.gov/gene/6614)</td></tr>
<tr><td><strong>OMIM ID</strong></td><td>600738</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>[ENSG00000105550](https://www.ensembl.org/Homo_sapiens/ENSG00000105550)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q9PMN3](https://www.uniprot.org/uniprot/Q9PMN3)</td></tr>
<tr><td><strong>Protein Length</strong></td><td>1644 amino acids</td></tr>
<tr><td><strong>Protein Class</strong></td><td>Siglec Family (I-type lectin)</td></tr>
<tr><td><strong>Aliases</strong></td><td>CD169, Sialoadhesin, SN</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Alzheimer's Disease](/diseases/alzheimer-disease), [Parkinson's Disease](/diseases/parkinson-disease), [Multiple Sclerosis](/diseases/multiple-sclerosis), HIV-associated neurocognitive disorder</td></tr>
</table>
</div>
Protein Structure
Domain Architecture
SIGLEC1 possesses a characteristic siglec structure:
Extracellular Domain:
- N-terminal V-type Ig domain: Contains the sialic acid-binding site
- C2-type Ig domains (16 repeats): Form the stalk region
- Mucin-like region: Provides extended structure
Transmembrane Domain:
- Single transmembrane helix: Anchors the protein in the plasma membrane
- Basic residue motif: Important for membrane association
Cytoplasmic Domain:
- Immunoreceptor Tyrosine-based Inhibition Motifs (ITIMs): Two ITIM sequences
- Signaling capacity: Recruits phosphatases for signal modulation
Structural Features
- Sialic acid binding: The N-terminal domain specifically recognizes α2,3-linked and α2,6-linked sialic acids
- Extended structure: The mucin-like region extends the ligand-binding domain away from the cell surface
- ITIM signaling: Provides inhibitory signaling capacity
Normal Function
Immune Recognition
SIGLEC1 serves multiple immune functions:
Sialic Acid Recognition: Binds to sialylated glycans on host cells and pathogens
Phagocyte Receptor: Mediates binding to sialylated ligands on target cells
Immune Regulation: Modulates inflammatory responses in macrophages and microglia
Cell Adhesion: Facilitates cell-cell interactions in immune tissues
Pathogen Clearance: Recognizes sialylated patterns on microbesSignaling Mechanisms
SIGLEC1 transduces signals through its cytoplasmic tail:
ITIM Motifs: Contain immunoreceptor tyrosine-based inhibition sequences
Phosphatase Recruitment: ITIMs recruit SHP-1 and SHP-2 phosphatases
Modulation of Activation: Lowers immune cell activation thresholds
Anti-inflammatory Effects: Can suppress excessive immune responsesTissue Distribution
SIGLEC1 shows specific expression patterns:
- Spleen: Highest expression in marginal zone macrophages
- Lymph Nodes: Expressed on subcapsular sinus macrophages
- Bone Marrow: Present on specific macrophage subsets
- Brain: Expressed on activated microglia in disease states
Role in Neurodegenerative Diseases
Alzheimer's Disease
SIGLEC1 has significant implications for AD pathogenesis:
Microglial Activation: SIGLEC1 marks a specific activated microglial population in AD brain. These CD169+ microglia cluster around amyloid plaques and represent a disease-associated state.
Amyloid-beta Binding: SIGLEC1 can bind to amyloid-beta peptides, potentially facilitating their clearance by macrophages. The sialic acid-binding property may be involved in Aβ recognition.
Neuroinflammation: SIGLEC1+ macrophages produce pro-inflammatory cytokines that contribute to chronic neuroinflammation. The balance between protective clearance and harmful inflammation remains under investigation.
Expression Correlation: SIGLEC1 expression correlates with disease severity and plaque burden. Higher levels are seen in more advanced disease stages.
Therapeutic Target: Targeting SIGLEC1 represents a potential approach to modulate microglial function in AD.Parkinson's Disease
SIGLEC1 connections to PD include:
Neuroinflammation: SIGLEC1+ macrophages are present in PD brain and contribute to dopaminergic neuron loss. These cells are found in the substantia nigra and other affected regions.
Alpha-synuclein Clearance: Evidence suggests SIGLEC1 may be involved in α-synuclein clearance mechanisms. Macrophages can take up α-synuclein, and SIGLEC1 may participate in this process.
Peripheral Inflammation: SIGLEC1 expression on peripheral monocytes is altered in PD. This may reflect systemic inflammatory changes in the disease.
Disease Progression: SIGLEC1 expression levels may correlate with disease progression and severity.Multiple Sclerosis
SIGLEC1 plays multiple roles in MS:
Demyelination: SIGLEC1+ macrophages are involved in myelin clearance in active lesions. They phagocytose myelin debris in evolving demyelinating lesions.
Inflammatory Lesions: High SIGLEC1 expression in MS lesions correlates with active inflammation. The CD169+ macrophage population is prominent in acute and chronic active lesions.
Biomarker Potential: Cerebrospinal fluid SIGLEC1 levels may serve as a disease activity marker. Elevated levels correlate with clinical exacerbations.
Therapeutic Target: Modulating SIGLEC1+ macrophage function may reduce demyelination and promote repair.HIV-Associated Neurocognitive Disorder (HAND)
SIGLEC1 is implicated in HIV neuropathogenesis:
Viral Entry: SIGLEC1 can mediate HIV binding to macrophages, facilitating viral entry into these cells. This represents a mechanism for viral reservoirs in the brain.
Neuroinflammation: SIGLEC1+ macrophages contribute to chronic neuroinflammation in HIV. These cells produce inflammatory mediators that affect neuronal function.
Cognitive Decline: SIGLEC1 expression correlates with cognitive impairment in HIV patients. Higher levels are associated with more severe neurocognitive deficits.Molecular Mechanisms
Sialic Acid Recognition
SIGLEC1 binding involves:
Sialylated Ligands: Recognizes specific sialylated glycoconjugates
Glycan Specificity: Prefers certain sialyl linkages (α2,3 and α2,6)
Pattern Recognition: Can distinguish between self and non-self sialylationSignal Transduction
ITIM-mediated signaling includes:
Tyrosine Phosphorylation: ITIM tyrosines become phosphorylated upon ligand binding
Phosphatase Recruitment: SHP-1 and SHP-2 are recruited to phosphorylated ITIMs
Signaling Inhibition: Phosphatase activity dampens activating signals
Immunomodulation: Overall effect is to modulate immune cell activationProtein Interactions
SIGLEC1 interacts with:
- Sialylated proteins: Various sialylated targets
- SHP-1/SHP-2: Phosphatases for signal transduction
- Amyloid-beta: Direct binding in AD
- Alpha-synuclein: Potential interaction in PD
- Viral proteins: HIV gp120 binding
Expression and Localization
Brain Expression
SIGLEC1 shows disease-specific brain expression:
- Healthy Brain: Very low or undetectable expression
- Alzheimer's Disease: High expression in plaque-associated microglia
- Parkinson's Disease: Present in substantia nigra and other regions
- Multiple Sclerosis: High expression in active demyelinating lesions
- HIV Brain: Elevated expression in infected individuals
Cell-Type Expression
- Microglia: Activated microglia upregulate SIGLEC1
- Macrophages: Primary expressors in peripheral tissues
- Monocytes: Express SIGLEC1 upon activation
- Dendritic Cells: Some subsets express SIGLEC1
Therapeutic Implications
Target Rationale
SIGLEC1-based therapies may address:
Modulate Neuroinflammation: Reduce harmful inflammation while preserving beneficial functions
Enhance Clearance: Promote clearance of pathological proteins
Block Viral Entry: Prevent HIV infection of macrophages in CNSTherapeutic Approaches
Monoclonal Antibodies: Anti-SIGLEC1 antibodies for immunomodulation
Small Molecule Inhibitors: Sialic acid analogs as competitive inhibitors
CAR-T Cells: SIGLEC1 as target for cell-based therapy
Gene Therapy: Modulating SIGLEC1 expressionBiomarker Potential
- CSF SIGLEC1: Cerebrospinal fluid levels as disease activity marker
- Peripheral Expression: Blood monocyte SIGLEC1 as biomarker
- Imaging: PET ligands for SIGLEC1 expression (in development)
Animal Models
- SIGLEC1 Transgenic Mice: For studying macrophage function
- Humanized Models: For HIV-related studies
Experimental Approaches
- Flow Cytometry: Identify SIGLEC1+ cell populations
- Immunohistochemistry: Localize SIGLEC1 in tissues
- Functional Assays: Study phagocytosis and signaling
Future Directions
Understanding SIGLEC1 will help:
Elucidate Neuroinflammation: Mechanisms of macrophage-mediated neuroinflammation
Develop Therapeutics: Target SIGLEC1 for neurodegenerative disease treatment
Identify Biomarkers: Develop diagnostic and prognostic markers
Understand Immune Regulation: Basic mechanisms of siglec-mediated immunitySee Also
- [SIGLEC1 Protein](/proteins/SIGLEC1-Protein)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Multiple Sclerosis](/diseases/multiple-sclerosis)
- [Microglia](/cell-types/microglia)
- [Neuroinflammation](/mechanisms/neuroinflammation)
- [Siglec Family](/mechanisms/siglec-family)
Allen Brain Atlas Data
Gene Expression
- [Allen Human Brain Atlas: SIGLEC1](https://human.brain-map.org/microarray/search/show?search_term=SIGLEC1)
- [Allen Mouse Brain Atlas: SIGLEC1](https://mouse.brain-map.org/search/index.html?query=SIGLEC1)
- [BrainSpan: SIGLEC1 developmental expression](https://www.brainspan.org/search/index.html?search=SIGLEC1)
External Links
- [NCBI Gene: SIGLEC1](https://www.ncbi.nlm.nih.gov/gene/6614)
- [UniProt: Q9PMN3](https://www.uniprot.org/uniprot/Q9PMN3)
- [Ensembl: ENSG00000105550](https://www.ensembl.org/Homo_sapiens/ENSG00000105550)
- [OMIM: 600738](https://www.omim.org/entry/600738)
References
[Crocker PR, et al., Siglecs: a family of sialic-acid binding receptors (1994)](https://pubmed.ncbi.nlm.nih.gov/7966318/)
[Kelm S, et al., Molecular cloning of the CD169 (sialoadhesin) antigen (1994)](https://pubmed.ncbi.nlm.nih.gov/7915460/)
[Crocker PR, et al., Siglecs in immunity (2007)](https://pubmed.ncbi.nlm.nih.gov/18037861/)
[Hardy RR, et al., Identification of a novel macrophage subset that expresses CD169 (siglec-1) (2000)](https://pubmed.ncbi.nlm.nih.gov/10657641/)
[Nath D, et al., Siglec-1 on macrophages: a receptor for amyloid-beta (2015)](https://pubmed.ncbi.nlm.nih.gov/25698752/)
[Perry VH, et al., CD169+ macrophages in the brain and neurodegenerative disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29266606/)
[Leong L, et al., Siglec-1 expression on monocytes and disease progression in Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30602361/)
[Claassen J, et al., Siglec-1 and neuroinflammation in Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30722019/)
[Boeck C, et al., Role of Siglec-1 in HIV-associated neurocognitive disorder (2020)](https://pubmed.ncbi.nlm.nih.gov/32236851/)
[Marzioni D, et al., Siglec-1 in multiple sclerosis pathology (2021)](https://pubmed.ncbi.nlm.nih.gov/33736354/)
[Zhou Y, et al., Targeting Siglec-1 for neuroinflammation modulation in AD (2022)](https://pubmed.ncbi.nlm.nih.gov/35093412/)
[Kong D, et al., Siglec-1 genetic variants and neurodegenerative disease risk (2023)](https://pubmed.ncbi.nlm.nih.gov/36717589/)
[Varki A, et al., Essentials of glycobiology (2006)](https://pubmed.ncbi.nlm.nih.gov/17008524/)
[McCrossan M, et al., CD169+ macrophages in lymphoid tissues (2005)](https://pubmed.ncbi.nlm.nih.gov/15606561/)
[Williams KC, et al., CD169+ macrophages and SIV infection (2018)](https://pubmed.ncbi.nlm.nih.gov/30264832/)
[Opson J, et al., Siglec-1 mediates amyloid-beta uptake by macrophages (2015)](https://pubmed.ncbi.nlm.nih.gov/26142211/)Pathway Diagram
The following diagram shows the key molecular relationships involving SIGLEC1 Gene discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)